Healthcare - Biotechnology - NASDAQ - GB
$ 1.79
-5.79 %
$ 7.77 M
Market Cap
-0.53
P/E
Price Target
Average
--100.00%
Revenue Forecast
Estimate
828.74%
EBIT
Estimate
--11.63%
Net Income
Estimate
45.57%
WALL STREET ESTIMATES
Wall Street Analysts Price Targets
Virax Biolabs Group Limited
VRAX has no price targets from Wall Street.
REVENUE FORECAST
Revenue Forecast Chart VRAX
EBIT FORECAST
EBIT Forecast Chart VRAX
NET INCOME FORECAST
Net Income Chart VRAX